Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis-Reference-Cited by-同舟云学术

Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis

Published:2016-08 Issue:8 Volume:4 Page:617-626
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

Elborn J Stuart,Ramsey Bonnie W,Boyle Michael P,Konstan Michael W,Huang Xiaohong,Marigowda Gautham,Waltz David,Wainwright Claire E

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference13 articles.

1. Searching for a cure for cystic fibrosis. A 25-year quest in a nutshell;Bosch;Eur J Pediatr,2016

2. Cystic fibrosis;O'Sullivan;Lancet,2009

3. Cystic Fibrosis Foundation Patient Registry 2013 Annual Data Report,2014

4. Targeting F508del-CFTR to develop rational new therapies for cystic fibrosis;Cai;Acta Pharmacol Sin,2011

5. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809;Van Goor;Proc Natl Acad Sci USA,2011

Cited by 130 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The burden of cystic fibrosis in North Africa;Frontiers in Genetics;2024-01-10

2. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del);Cochrane Database of Systematic Reviews;2023-11-20

3. Fibrosis quística: epidemiología, clínica, diagnóstico y tratamiento;Medicina Clínica;2023-11

4. Cystic fibrosis: Epidemiology, clinical manifestations, diagnosis and treatment;Medicina Clínica (English Edition);2023-11

5. How representative are clinical trial cohorts of the general CF population? Implications for trial planning;Journal of Cystic Fibrosis;2023-11